Infectious Disease Alert – June 1, 2011
June 1, 2011
View Issues
-
Abstract & Commentary: Measles — It's Back!
On Feb. 15, 2011, a 30-month-old U.S.-born child of Somali descent developed a skin rash 14 days after returning from a trip to Kenya and 1 day after visiting a child care center. -
Abstract & Commentary: The FDA and Food Safety Regulation
Basically, people now feel nothing is safe to eat. They don't know what choices to make. -
Abstract & Commentary: Triple Therapy for Hepatitis C — Boceprevir vs. Telaprevir
The April 14 issue of the New England Journal of Medicine contains two articles on boceprevir, a new designer molecule that has demonstrated a dramatic improvement in outcomes for patients with genotype 1 hepatitis C. -
Abstract & Commentary: Herpes Zoster Vaccination Indication Extended to Younger Individuals
ZOSTAVAX®, which had previously received FDA approval for prevention of herpes zoster (HZ) and post-herpetic neuralgia in individuals 60 years of age and older, had its approval extended to include people 50-59 years of age on March 24, 2011. -
Abstract & Commentary: Treatment of HHV-8-related Disease with Antivirals
Uldrick et al performed a pilot study in which 14 HIV-infected patients with symptomatic MCD received high-dose AZT (600 mg PO Q6 hours) and VGC (900 mg PO Q12 hours). -
Abstract & Commentary: Identifying Children with Primary Immunodeficiency Diseases
A retrospective study was conducted of 563 children who presented over the last decade to two pediatric immunodeficiency centers in the United Kingdom. -
Abstract & Commentary: A New Indication for HPV Vaccination — Prevention of Anal Cancer
GARDASIL® (Human Papillomavirus Quadrivalent [Types 6, 11, 16, 18] Vaccine, Recombinant) previously received FDA approval for prevention of cervical, vulvar, and vaginal cancer and associated precancerous lesions, and for prevention of genital warts in males and females 9-26 years of age. -
Abstract & Commentary: cART Start
In a prospective observational study, investigators of the HIV-CAUSAL Collaboration evaluated data from participating HIV clinics in Europe and the U.S. Veterans Administration system to determine the optimal CD4+ T cell count at which combination antiretroviral therapy (cART) should be initiated. -
Updates By Carol A. Kemper, MD, FACP
Coccidioidal infections are always unique the travel history often provides the right clue for the practitioner but first you have to think to ask the right question. -
Pharmacology Watch: Women's Health Issue — Adverse Medication Effects
In this issue: Calcium supplements and MI; birth control pills and VTE; ACE inhibitors and breast cancer risk; spending on pharmaceuticals; and FDA actions. -
Clinical Briefs in Primary Care supplement